{"id":422,"date":"2025-11-14T04:02:21","date_gmt":"2025-11-14T04:02:21","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=422"},"modified":"2025-11-14T04:02:22","modified_gmt":"2025-11-14T04:02:22","slug":"china-bd-2025-degron-therapeutics-and-msd-enters-a-license-on-fic-molecular-glue-degraders","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/422.html","title":{"rendered":"[China BD 2025] Degron Therapeutics and MSD enters a License on FIC Molecular Glue Degraders"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2025-11-13 (November 11, 2025)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor (Seller): Degron Therapeutics (China)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee (Buyer): \u00a0MSD R&amp;D (China)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Modality: Molecular Glue Degraders<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Leverage Degron\u2019s GlueXplorer platform and MSD\u2019s clinical expertise in oncology and rare diseases<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Payment Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Undisclosed.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/flcube.com\/?p=47648\">Degron Therapeutics, MSD\u202fR&amp;D, and the Next Generation of Molecular Glue Degraders &#8211; Insight, China&#8217;s Pharmaceutical Industry (flcube.com)<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Note:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chinese Name of Degron Therapeutics \u8fbe\u6b4c\u751f\u7269<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-11-13 (November 11, 2025) Licensor (Seller): Degron Therapeutics (China) Licensee (Buyer): \u00a0MSD R&amp;D (China) &hellip; <a title=\"[China BD 2025] Degron Therapeutics and MSD enters a License on FIC Molecular Glue Degraders\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/422.html\"><span class=\"screen-reader-text\">[China BD 2025] Degron Therapeutics and MSD enters a License on FIC Molecular Glue Degraders<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-422","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/422","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=422"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/422\/revisions"}],"predecessor-version":[{"id":423,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/422\/revisions\/423"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=422"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=422"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}